Abcam has completed a $340m strategic acquisition of BioVision and doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam’s growth in the US, which the company says will enable it to support the research and biopharma sector globally.
The addition of BioVision enhances Abcam’s in-house innovation and adds scale to support the biochemical assay and cellular assay markets. The acquisition brings BioVision’s product portfolio, capabilities, and expert development and manufacturing teams into Abcam. The global research community will gain access to this portfolio of biochemical and cell-based assays via Abcam’s commercialisation network.
Alan Hirzel, CEO at Abcam, said: “We are delighted to welcome our new colleagues to Abcam. Providing a platform for future growth and addition of new product lines, the acquisition of BioVision and expansion of our Eugene facility reinforces our commitment to the acceleration of scientific breakthroughs. Enabling scientists to reproducibly generate the robust results they need, faster, is essential for the delivery of new innovations that can positively impact us all.”